Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OVV-01 + ivonescimab
- Development stage
- Unknown
- Lead developer
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
OVV-01 + AK112 is an investigational combination therapy comprising OVV-01, an oncolytic virus, and AK112 (ivonescimab), a bispecific antibody targeting programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF). OVV-01 is a biologic agent designed to selectively infect and lyse tumor cells while stimulating a systemic anti-tumor immune response. AK112 simultaneously inhibits the PD-1/PD-L1 immune checkpoint and the VEGF-mediated angiogenic pathway, potentially enhancing immune-mediated tumor destruction and normalizing tumor vasculature. This combination is being evaluated in Phase II clinical trials for the treatment of advanced (metastatic or recurrent unresectable) soft tissue sarcoma (STS). The studies are primarily sponsored by the Cancer Institute and Hospital, Chinese Academy of Medical Sciences.
- Other names
- OVV-01 + ivonescimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on OVV-01 + ivonescimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OVV-01 + ivonescimab.